Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4). [VICRIVIROC in trattamento combinato con un regime ART ottimale in pazienti affetti da HIV pretrattati (VICTOR E4).]
Latest Information Update: 01 Sep 2022
At a glance
- Drugs Vicriviroc (Primary)
- Indications HIV-1 infections
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms VICTOR-E4
- Sponsors Merck Sharp & Dohme Corp.
- 13 Jan 2014 Actual end date changed as reported in ClinicalTrials.gov record.
- 15 Mar 2010 Status changed from active, no longer recruiting to completed.
- 20 Feb 2010 Primary endpoint 'Virological response rate' has not been met; results reported at CROI 2010.